200,000+ products from a single source!
sales@angenechem.com
147403-03-0 | 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-
CAS No: 147403-03-0 Catalog No: AG001EVU MDL No:MFCD20278186
Product Description
Catalog Number:
AG001EVU
Chemical Name:
1H-Benzimidazole-7-carboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-
CAS Number:
147403-03-0
Molecular Formula:
C25H20N4O5
Molecular Weight:
456.4501
MDL Number:
MFCD20278186
IUPAC Name:
2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
InChI:
InChI=1S/C25H20N4O5/c1-2-33-24-26-20-9-5-8-19(23(30)31)21(20)29(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-27-25(32)34-28-22/h3-13H,2,14H2,1H3,(H,30,31)(H,27,28,32)
InChI Key:
KGSXMPPBFPAXLY-UHFFFAOYSA-N
SMILES:
CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1[nH]oc(=O)n1)c(ccc2)C(=O)O
EC Number:
808-058-6
UNII:
F9NUX55P23
Properties
Complexity:
783
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
456.143g/mol
Formal Charge:
0
Heavy Atom Count:
34
Hydrogen Bond Acceptor Count:
7
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
456.458g/mol
Monoisotopic Mass:
456.143g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
115A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.4
Literature
| Title | Journal |
|---|---|
| Azilsartan and its Zn(II) complex. Synthesis, anticancer mechanisms of action and binding to bovine serum albumin. | Toxicology in vitro : an international journal published in association with BIBRA 20180401 |
| Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial. | Hypertension research : official journal of the Japanese Society of Hypertension 20140901 |
| Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. | Clinical therapeutics 20140501 |
| Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1. | Chemosphere 20120601 |
| Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. | Hypertension research : official journal of the Japanese Society of Hypertension 20120501 |
| Differential pharmacology and benefit/risk of azilsartan compared to other sartans. | Vascular health and risk management 20120101 |
| Critical evaluation of the efficacy and tolerability of azilsartan. | Vascular health and risk management 20120101 |
| Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. | Vascular health and risk management 20120101 |
| Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. | Diabetes, obesity & metabolism 20111201 |
| Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. | Journal of clinical hypertension (Greenwich, Conn.) 20110701 |
| In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. | The Journal of pharmacology and experimental therapeutics 20110301 |
| Azilsartan: a newly approved angiotensin II receptor blocker. | Cardiology in review 20110101 |
| TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. | American journal of hypertension 20070501 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.